

desloratadine/pseudoephedrine (CLARINEX-D)

Diagnosis Considered for Coverage:

Seasonal Allergic Rhinitis

Coverage Criteria:

For diagnosis listed above:

- Inadequate response to desloratadine tablet (Clarinex) and
- Dose does not exceed FDA label maximum

Coverage Duration: one year

Effective Date: 09/27/2023